![apnealink driver windows 7 apnealink driver windows 7](https://image.irislink.com/Products/IRIScan_Express_4/Header-2.png)
The objective of this study was to evaluate the performance of the ApneaLink HST, including the autoscoring algorithm, to diagnose OSA in a population of obese pregnant women.
![apnealink driver windows 7 apnealink driver windows 7](http://softisri.weebly.com/uploads/1/2/4/8/124850718/865672339.jpg)
#Apnealink driver windows 7 software
The recorded signals can be analyzed automatically by the ApneaLink software platform to generate an “autoscore” but can also be reviewed, edited, and rescored by a sleep technician within the same software package. It consists of 3 recommended and validated sensors for measuring respiration: a nasal pressure transducer (that measures nasal airflow and waveform, which are needed for the detection of apneas and hypopneas and airflow limitation), a thoracic inductance plethysmography band that measures respiratory effort for distinguishing central from obstructive apneas (and as a back-up for the nasal pressure signal), and finger pulse oximetry (to quantify the level and duration of oxygen desaturation). The ApneaLink (ResMed, Sydney, Australia) is a pocket-sized type III home sleep testing device. Currently there are little data on the use of HST in pregnancy, specifically on how autoscoring algorithms perform in pregnancy compared to both technician review of HST recordings and in-house polysomnography. Therefore, it is imperative that we do more to understand how HST performs in pregnancy. Epidemiologic data demonstrate that the vast majority of OSA identified in pregnancy is mild in severity however not extending the option of home sleep testing to pregnant women could significantly limit the ability to diagnose and treat OSA in this vulnerable patient population. The American Academy of Sleep Medicine comments that although it is less sensitive than polysomnography in the detection of OSA, a type III HST can be ordered by a physician for the diagnosis of OSA when the physician has determined that the patient does not have other medical conditions or risk for other sleep disorders that would preclude the use of an HST and has identified signs and symptoms that indicate an increased risk of moderate to severe OSA, rather than mild OSA. If ongoing research results continue to support the role of screening for sleep apnea in pregnancy, it will be important to optimize the use of HST to help care providers quickly triage which pregnant women are at greatest need of possible treatment of referral to a sleep expert as long delays for in-lab PSG cannot be tolerated with a time-limited situation as pregnancy. Type III home sleep testing (HST) devices with autoscoring capabilities may lessen the burden of testing for OSA in pregnancy however data regarding their reliability in pregnancy are limited. However, there are limited data on best practices to screen for and treat OSA in pregnancy. In a large epidemiologic study of OSA in pregnancy, about 15% of women with a BMI ≥ 30 had evidence of sleep apnea in the first trimester pregnancy, and the rate doubles to 30% when retested in mid-pregnancy. Obstructive sleep apnea (OSA) in pregnancy has been associated with adverse maternal and neonatal outcomes.